Don’t Trade in the Dark—Get Your Pre-Market Report Every Day.Join Now
Pharmaceuticals & Biotechnology | Small Cap
Health Score : 5.73Medicamen Biotech Ltd demonstrates a mixed financial performance. The company showcases strong solvency and profitability, indicating a stable financial structure and good earnings capability. Its revenue and asset growth are also positive signs. However, the company faces challenges in efficiency, particularly in managing inventory and receivables. Additionally, there's been a decline in operating profit, EPS, and net income growth recently. While the company maintains a reasonable liquidity position, there are areas needing improvement. The healthcare industry's dynamics, including regulatory changes and market competition, could further impact Medicamen Biotech's financial trajectory. Overall, Medicamen Biotech presents a picture of a company with solid foundations but facing some operational hurdles.
Health Score : 5.73Medicamen Biotech Ltd demonstrates a mixed financial performance. The company showcases strong solvency and profitability, indicating a stable financial structure and good earnings capability. Its revenue and asset growth are also positive signs. However, the company faces challenges in efficiency, particularly in managing inventory and receivables. Additionally, there's been a decline in operating profit, EPS, and net income growth recently. While the company maintains a reasonable liquidity position, there are areas needing improvement. The healthcare industry's dynamics, including regulatory changes and market competition, could further impact Medicamen Biotech's financial trajectory. Overall, Medicamen Biotech presents a picture of a company with solid foundations but facing some operational hurdles.
Overall Valuation Score
Markets Depth NSE
Buy Orders
Bid
Quantity
Orders
No buy depth
Total
0
0
Sell Orders
Ask
Quantity
Orders
No sell depth
Total
0
0
Markets Today NSE
High
0.00
Low
0.00
Open
0.00
Close
0.00
Prev Close
0.00
Avg Price
0.00
Volume
0
Last Traded Quantity
0
Last Traded Time
N/A
Price Movement Indicator
Today's Low: 0.00
Today's High: 0.00
P/E RATIO (TTM)
38.53
Industry Median
30.91
Small Cap Median
28.64
P/E RATIO
37.61
P/B RATIO
1.32
Industry Median
3.69
Small Cap Median
3.11
P/S RATIO
1.88
Industry Median
3.74
Small Cap Median
3.02
Others
PEG RATIO
0.00
EV/EBITDA RATIO
15.09
The Calculations Shown Above Are Based on the Last Traded Price (LTP) of ₹267.4 as on Sep 1, 2026.
Growth Score : 4.80The company's revenue and asset growth are positive, but its operating profit, earnings per share, and net income are declining. While revenue and assets are increasing, profitability is decreasing. This is a point of concern for the company. The company needs to improve on its profitability.
Revenue Growth RateExcellent
Operating Profit Growth RatePoorEarnings Per Share (EPS) GrowthPoorAsset Growth RateExcellentNet Income Growth RatePoor| Growth Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue Growth Rate | 1.77 | 22.61 | 26.95 | -8.94 | 21.47 |
| Operating Profit Growth Rate | 20 | 0 | 0 | -41.67 | 42.86 |
| Earnings Per Share (EPS) Growth | 22.86 | -3.85 | -26.68 | -35 | 27.19 |
| Asset Growth Rate | 16.49 | 23.45 | 5.73 | 0.68 | 25.25 |
| Net Income Growth Rate | 25 | 0 | -40 | -22.22 | 42.86 |
Revenue Growth Rate
Operating Profit Growth Rate
Earnings Per Share (EPS) Growth
Asset Growth Rate
Net Income Growth Rate
Peer Comparison empowers investors to evaluate a company against its industry peers using key financial metrics like P/E ratio, EPS, and profit margins. It helps identify whether a company is overvalued, undervalued, or performing in line with competitors. Investors can use this data to spot opportunities, assess risks, and make informed decisions. This contextual view adds depth beyond standalone company analysis.
| NO | Company Name | Health Score | P/E Ratio | Valuation | OPM | EPS | Latest Profit & Loss |
|---|---|---|---|---|---|---|---|
| 1 | Accent Microcell Ltd | 7.96 | 24.25 | Neutral | 57.00 | 18.28 | 44.00 |
| 2 | Kilitch Drugs (India) Ltd | 7.12 | 22.83 | Neutral | 37.00 | 9.27 | 30.00 |
| 3 | NGL Fine Chem Ltd | 6.98 | 34.11 | Neutral | 73.00 | 67.39 | 48.00 |
| 4 | Sakar Healthcare Ltd | 6.89 | 70.49 | Highly Overvalued | 69.00 | 13.70 | 30.00 |
| 5 | Medico Remedies Ltd | 6.61 | 37.70 | Overvalued | 17.00 | 1.58 | 13.00 |
| 6 | Kopran Ltd | 6.60 | 40.82 | Undervalued | 62.00 | 6.30 | 26.00 |
| 7 | SMS Lifesciences India Ltd | 6.59 | 22.25 | Undervalued | 45.00 | 58.80 | 19.00 |
| 8 | Infinium Pharmachem Ltd | 6.42 | 33.97 | Neutral | 22.00 | 6.43 | 14.00 |
| 9 | Medicamen Biotech Ltd | 5.73 | 37.61 | Neutral | 20.00 | 6.94 | 10.00 |
| 10 | Aarey Drugs & Pharmaceuticals Ltd | 5.73 | 60.35 | Neutral | 7.00 | 1.40 | 4.00 |
| 11 | Albert David Ltd | 5.63 | -333.98 | Neutral | 5.00 | -2.62 | -1.00 |
| 12 | BPL Ltd | 5.46 | -28.58 | Neutral | -4.82 | -1.69 | -8.55 |
| 13 | Zim Laboratories Ltd | 5.41 | 108.20 | Neutral | 30.00 | 1.11 | 6.00 |
| 14 | Remus Pharmaceuticals Ltd | 5.31 | 27.61 | Neutral | 57.00 | 20.97 | 46.00 |
| 15 | Ind-Swift Laboratories Ltd | 4.95 | 77.18 | Neutral | 45.00 | 4.89 | 41.00 |
| 16 | Lyka Labs Ltd | 4.77 | -26.63 | Neutral | -4.00 | -8.93 | -10.00 |
| 17 | Wanbury Ltd | 4.65 | 27.30 | Neutral | 88.00 | 15.98 | 43.00 |
| 18 | Nectar Lifescience Ltd | 3.83 | -0.80 | Neutral | -59.00 | -2.95 | -293.00 |
0 Credits RemainingUnlock Deep Technical Insights in Seconds Only with Dhanarthi AI
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Market Sentiment
Analysis Driven By 26 Technical Indicators From The 1 Hour Timeframe
Trend Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Momentum Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Volatility Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Volume Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Analyzing moving average trends and crossovers. Green/Red badges indicate if the current condition passes or fails.
Comparing stock price performance (normalized) against benchmark indices over time.
Recent daily trading volume represented as a bar chart, alongside historical averages.
Current closing price relative to the 52-week highest and lowest prices.
No Stock Reports Available at This Moment.
Medicamen Biotech Ltd. is an Indian pharmaceutical company engaged in the manufacturing, marketing, and distribution of a diverse portfolio of pharmaceutical formulations. It specializes in various dosage forms like tablets, capsules, liquid orals, and injectables, serving both the domestic and international markets with a strong focus on quality and accessibility.
P/E Ratio (TTM): Price to Earnings ratio shows how much an investor pays for every rupee of the company's earnings. Medicamen Biotech Ltd's P/E ratio (TTM) is 38.53, compared to the industry median of 30.91 and large cap median of 28.64.
P/B Ratio: Price to Book ratio compares a company's market price to its book value per share. Medicamen Biotech Ltd's P/B ratio is 1.32, compared to the industry median of 3.69 and large cap median of 3.11.
P/S Ratio: Price to Sales ratio compares a company's market value to its total revenue. Medicamen Biotech Ltd's P/S ratio is 1.88, compared to the industry median of 3.74 and large cap median of 3.02.
PEG Ratio: PEG ratio adjusts the P/E ratio for expected earnings growth. Medicamen Biotech Ltd's PEG ratio is N/A.
EV/EBITDA Ratio: This ratio compares a company's enterprise value to its earnings before interest, tax, depreciation, and amortization. Medicamen Biotech Ltd's EV/EBITDA ratio is 15.09.
Return on Equity (ROE): ROE measures how much profit a company generates from shareholders' invested capital. Medicamen Biotech Ltd's ROE is 3.62%.
Return on Assets (ROA): ROA measures how efficiently a company converts its assets into net profit. Medicamen Biotech Ltd's ROA is 5.38%.
Return on Capital Employed (ROCE): ROCE measures how efficiently a company generates profit from all the capital it employs. Medicamen Biotech Ltd's ROCE is 5%.
Operating Margin: Operating margin shows what percentage of revenue remains after covering operating expenses. Medicamen Biotech Ltd's operating margin is 10.10%.
Net Margin: Net margin shows what percentage of revenue converts into final net profit. Medicamen Biotech Ltd's net margin is 5.05%.
Current Ratio: The current ratio measures a company's ability to pay short-term liabilities using short-term assets. Medicamen Biotech Ltd's current ratio is 3.17.
Debt to Equity Ratio: This ratio shows the proportion of debt a company uses relative to shareholders' equity. Medicamen Biotech Ltd's debt-to-equity ratio is 0.02.
Interest Coverage Ratio: This ratio shows how easily a company can pay interest on its outstanding debt from its operating earnings. Medicamen Biotech Ltd's interest coverage ratio is 4.
Dividend Per Share (DPS): DPS shows the total dividend paid per share in the latest financial year. Medicamen Biotech Ltd's DPS is ₹1.
Earnings Per Share (EPS): EPS shows how much profit is allocated to each outstanding share. Medicamen Biotech Ltd's EPS is 27.19.
(Source line: "Ratios as of 25 Sept 2026, based on last traded price of ₹267.40. Data sourced from BSE/NSE Exchange Filings & Public Terminal Data.")
Founded: 1993
Headquarters: New Delhi, Delhi
Core Offerings: Tablets, Capsules, Liquid Orals, Injections, External Preparations
Stock Listing: NSE (MEDICAMEQ), BSE (531146)
Promoter: Gupta Family
Medicamen Biotech Limited was incorporated in 1993, commencing its commercial production of pharmaceutical formulations at its Haridwar facility in 1995. The company was listed on both NSE and BSE in 1998, marking its entry into public markets. Over the years, it has expanded its manufacturing capabilities and product portfolio, developing a strong presence in international markets, particularly across Africa, Latin America, and Southeast Asia. Today, Medicamen Biotech continues to be a key player in the Indian pharmaceutical sector, focusing on quality manufacturing and global outreach.
| Segment Name | Revenue % | EBITDA |
|---|---|---|
| Pharmaceutical Products | 100% | Operating Profit |
Pharmaceutical Formulations: Manufactures a comprehensive range of dosage forms including tablets, capsules, liquid orals, injections (dry powder and liquid), and external preparations.
Contract Manufacturing: Offers third-party manufacturing services, leveraging its state-of-the-art, regulatory-compliant facilities to produce formulations for other pharmaceutical companies.
International Business: Exports a wide array of products to over 70 countries across Africa, Latin America, CIS regions, and Southeast Asia, adhering to diverse international regulatory standards.
Domestic Business: Caters to the Indian pharmaceutical market with its own branded prescription and over-the-counter (OTC) products.
Mr. Rahul Kumar Gupta: Managing Director. An MBA by qualification, he brings extensive experience in the pharmaceutical industry, having played a pivotal role in driving the company's operational excellence and expanding its global footprint.
Medicamen Biotech Holdings Limited (Mauritius)
Medicamen Pharma (Proprietary) Limited (South Africa)
Medicamen Biotech (USA) Inc. (USA)
Medicamen Biotech (Singapore) Pte. Ltd. (Singapore)
Stock Split (Face Value from ₹10 to ₹1) effective February 2024.
The Medicamen Biotech Ltd share price today is ₹267.40 on NSE (MEDICAMEQ), as of 26 Sept 2026.
As of 25 Sept 2026, Medicamen Biotech Ltd share price is ₹267.40, with previous close ₹267.40. Today's range is ₹267.40 to ₹267.40. The 52-week range is ₹212.40 to ₹424.10.
As of today, Medicamen Biotech Ltd's market cap is ₹371.69 crore (Small Cap).
Medicamen Biotech Ltd's current P/E ratio is 38.53, compared to the PHARMACEUTICALS & BIOTECHNOLOGY sector average of N/A.
Medicamen Biotech Ltd's current P/B ratio is 1.32.
Medicamen Biotech Ltd's current dividend yield is 0.37%. Last dividend of ₹0.10 per share was declared on 28-Oct-2023.
Medicamen Biotech Ltd's EPS (TTM) is ₹27.19.
Medicamen Biotech Ltd. is an Indian pharmaceutical company engaged in the manufacturing, marketing, and distribution of a diverse portfolio of pharmaceutical formulations. It specializes in various dosage forms like tablets, capsules, liquid orals, and injectables, serving both the domestic and international markets with a strong focus on quality and accessibility.
Medicamen Biotech Ltd is promoted by Gupta Family, holding 40.46% as of 25 Sept 2026.
Medicamen Biotech Ltd is listed on NSE (MEDICAMEQ) and BSE (531146). Its next quarterly results are expected on May 2024.
